JP2010515756A5 - - Google Patents

Download PDF

Info

Publication number
JP2010515756A5
JP2010515756A5 JP2009545699A JP2009545699A JP2010515756A5 JP 2010515756 A5 JP2010515756 A5 JP 2010515756A5 JP 2009545699 A JP2009545699 A JP 2009545699A JP 2009545699 A JP2009545699 A JP 2009545699A JP 2010515756 A5 JP2010515756 A5 JP 2010515756A5
Authority
JP
Japan
Prior art keywords
oxo
carbonyl
hydroxy
pyridazinyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009545699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010515756A (ja
JP5313925B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/050833 external-priority patent/WO2008089052A2/en
Publication of JP2010515756A publication Critical patent/JP2010515756A/ja
Publication of JP2010515756A5 publication Critical patent/JP2010515756A5/ja
Application granted granted Critical
Publication of JP5313925B2 publication Critical patent/JP5313925B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009545699A 2007-01-12 2008-01-11 Ｎ置換グリシン誘導体：ヒドロキシラーゼ阻害剤 Expired - Fee Related JP5313925B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88471007P 2007-01-12 2007-01-12
US60/884,710 2007-01-12
PCT/US2008/050833 WO2008089052A2 (en) 2007-01-12 2008-01-11 N-substituted glycine derivatives: hydroxylase inhibitors

Publications (3)

Publication Number Publication Date
JP2010515756A JP2010515756A (ja) 2010-05-13
JP2010515756A5 true JP2010515756A5 (https=) 2011-01-27
JP5313925B2 JP5313925B2 (ja) 2013-10-09

Family

ID=39636631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545699A Expired - Fee Related JP5313925B2 (ja) 2007-01-12 2008-01-11 Ｎ置換グリシン誘導体：ヒドロキシラーゼ阻害剤

Country Status (20)

Country Link
US (2) US7608621B2 (https=)
EP (2) EP2124565B1 (https=)
JP (1) JP5313925B2 (https=)
KR (1) KR101458655B1 (https=)
CN (1) CN101626685B (https=)
AR (1) AR064878A1 (https=)
AU (1) AU2008206441B2 (https=)
BR (1) BRPI0806566A2 (https=)
CA (1) CA2675252C (https=)
CL (1) CL2008000066A1 (https=)
DK (1) DK2124565T3 (https=)
EA (1) EA017112B1 (https=)
ES (2) ES2528745T3 (https=)
HR (1) HRP20150119T1 (https=)
MX (1) MX2009007548A (https=)
PL (1) PL2124565T3 (https=)
PT (1) PT2124565E (https=)
SI (1) SI2124565T1 (https=)
TW (1) TW200845991A (https=)
WO (1) WO2008089052A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI336260B (en) * 2002-07-25 2011-01-21 Glaxo Group Ltd Dosage form suitable for retaining drug substance
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
ITMI20051085A1 (it) * 2005-06-10 2006-12-11 Acs Dobfar Spa Metodo di purificazione del cefotetan
US8450351B2 (en) * 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036642A2 (en) * 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
WO2010025087A1 (en) * 2008-08-25 2010-03-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2010055884A1 (ja) * 2008-11-13 2010-05-20 日本農薬株式会社 ピラジン誘導体類の製造方法及びその中間体類
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
DE102009004061A1 (de) * 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
EP3594213A1 (en) * 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
KR101665749B1 (ko) * 2009-10-21 2016-10-12 다이이찌 산쿄 가부시키가이샤 5-하이드록시피리미딘-4-카르복사미드 유도체
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
WO2011115687A2 (en) * 2010-03-19 2011-09-22 Northwestern University Alkylated sp-b peptoid compounds and related lung surfactant compositions
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (https=) 2011-06-06 2018-03-17
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013063221A1 (en) 2011-10-25 2013-05-02 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
TWI583670B (zh) 2012-07-30 2017-05-21 大正製藥股份有限公司 Partially saturated nitrogenous heterocyclic compounds
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
ES2799582T3 (es) 2013-11-08 2020-12-18 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
WO2021127273A1 (en) * 2019-12-20 2021-06-24 Gb004, Inc. 1 -((6-oxo-1,6-dihydropyridazin-4-yl)methyl)piperazine and 1 -((6-oxo-1,6-dihydropyrimidin-4-yl)methyl)piperazine derivatives as prolyl hydroxylase, hif-1 alpha and pgk modulators for use in treating inflammatory diseases, cancer or infections
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149485T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
AU2003225088A1 (en) 2002-04-19 2003-11-03 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
WO2008040002A2 (en) 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
US20100003190A1 (en) 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands

Similar Documents

Publication Publication Date Title
JP2010515756A5 (https=)
RU2462454C2 (ru) Новое сульфонамидное производное малоновой кислоты и его фармацевтическое применение
EP2589592A1 (en) Novel nicotinamide derivatives or salts thereof
JP2007524696A5 (https=)
DK2406226T3 (en) Substituted nikotinamider as a KCNQ2 / 3 modulators
JP2019034943A5 (https=)
EP1803709B1 (en) Proton pump inhibitors
JP5225076B2 (ja) チアゾール環を含むカルボン酸誘導体の医薬用途
JP2008531599A5 (https=)
JP2015531769A5 (https=)
JP2014528403A5 (https=)
ZA200401777B (en) Novel 1,24-triazole compound
RU2013126251A (ru) Производные гетероарилсульфонамидов, их получение и применение для лечения человека
JP2020522520A5 (https=)
JP2015503529A5 (https=)
WO2005123680B1 (en) Six-membered heterocycles useful as serine protease inhibitors
JP2016513660A5 (https=)
JP2007529486A5 (https=)
JP2004524301A5 (https=)
JP2013516479A5 (https=)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
CA2665476A1 (en) Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
CA2690953A1 (en) Benzimidazole derivatives
JP2007519694A5 (https=)
CA2679232A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof